Compounded Semaglutide in 2026: What the Shortage Designation Changes for Providers

The FDA drug shortage list has become one of the most consequential regulatory documents in outpatient medicine. For practices prescribing semaglutide — whether for type 2 diabetes management or weight loss — the shortage designation determines whether compounded versions are legally available, and under what conditions.

This guide explains exactly where things stand in 2026, what the designation means in practice, and how licensed providers can protect their supply chain.

Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may produce copies of commercially available drugs under specific circumstances. One of the most important is when the branded drug appears on the FDA's official drug shortage list.

When semaglutide (Ozempic, Wegovy, Rybelsus) is on the shortage list:

• 503A pharmacies may compound semaglutide for individual patient prescriptions from licensed practitioners
• 503B outsourcing facilities may produce larger batches for distribution to licensed healthcare facilities and practices
• Compounded versions do not require FDA approval but must meet cGMP standards and use USP-grade API

When a drug is removed from the shortage list, the legal basis for compounding that specific molecule narrows significantly. Providers who have built programs around compounded semaglutide need to understand this distinction.

The FDA has updated semaglutide's shortage designation multiple times since 2023. As of mid-2026:

• Semaglutide injection (the active ingredient in Ozempic and Wegovy) has experienced fluctuating shortage status at various dosage strengths
• The FDA has issued guidance distinguishing between shortage-based compounding and what it considers "essentially a copy" of a branded product
• Several 503B outsourcing facilities have received warning letters for producing compounded semaglutide after shortage designations were lifted for specific strengths

The practical implication: not all semaglutide compounding is created equal, and the legal basis for your supply depends on the specific dosage form, strength, and the current shortage status at the time of ordering.

Reputable 503A and 503B facilities track shortage designations in real time and adjust their production accordingly. When evaluating a compounding supplier, ask:

1. Do they monitor the FDA shortage list daily? Shortage status can change with little notice.
2. Do they produce only shortage-designated strengths? Producing non-shortage strengths without a valid compounding rationale is a compliance risk.
3. Are they IRB-enrolled? IRB enrollment provides an additional layer of oversight and documentation for research-adjacent compounding.
4. What is their API sourcing? All API should be USP-grade, sourced from FDA-registered facilities.

At MedClinic Partners, our 503A and 503B partner facilities maintain real-time shortage monitoring and adjust production schedules accordingly. Providers on our portal are notified of any supply changes before they affect order fulfillment.

If you are sourcing compounded semaglutide, verify that your supplier has documentation confirming:

• Current shortage designation for the specific strength you are ordering
• cGMP compliance and recent third-party testing certificates
• 503A or 503B registration with the FDA

Tirzepatide (Mounjaro, Zepbound) has maintained a more consistent shortage designation through 2026. Retatrutide, while not yet FDA-approved, is available through IRB-enrolled research programs. Practices that rely on a single molecule are more exposed to supply disruption.

For 503A compounding, the prescription must be for an identified individual patient with a legitimate medical need. Bulk ordering without patient-specific prescriptions is a compliance violation regardless of shortage status.

The FDA has issued multiple guidance documents on compounding since 2023. Key documents to bookmark:

• FDA Guidance on Compounding Under Sections 503A and 503B
• FDA Drug Shortage Database (updated daily)
• FDA Warning Letters database (search for compounding)

Compounded semaglutide remains legally available through compliant 503A and 503B channels as long as shortage designations support it. The risk is not in the compound itself — it is in sourcing from facilities that are not tracking regulatory status in real time or that are cutting corners on cGMP compliance.

Practices that partner with verified, shortage-aware suppliers and maintain proper prescribing documentation are well-positioned regardless of how the shortage designation evolves.

If you are a licensed provider looking to establish a compliant semaglutide supply chain, the MedClinic Partners portal provides instant NPI verification and same-day access to shortage-compliant 503A and 503B supply.